Abstract
Objective: The aim of this study is to develop and in vitro evaluation of prepared fluconazole nanogel for seborrheic dermatitis
 Methods: Fluconazole nanogel was formulated to act against seborrheic dermatitis. The fluconazole nanoparticles were prepared by a simplified evaporation method and evaluated for particle size, entrapment efficiency, and percent in vitro drug release. The nanogel was also characterized based on parameters like particle size, percent entrapment efficiency, shape surface morphology, rheological properties, in vitro release R² = 0.9046, and release kinetics.
 Results: The nanoparticle with a combination of Eudragit RS and Tween 80 showed the best result with particle size in the range of 119.0 nm to 149.5 nm, with a cumulative percent drug release of 95 % up to 18 h. The formulated nanogel with optimum concentration of HPMC authenticate with particle size 149.50±0.5 with maximum drug release (92.13±0.32) %.
 Conclusion: Different percentages of polymers (ethyl-cellulose, eudragit, and tween 80) are used as variable components in the formulation of nanogel. The optimized batch showed good physical properties (flow index, spreadability, and viscosity) along with rapid drug release. Therefore, it can be concluded that nanogel containing fluconazole has potential application in topical delivery.
Highlights
Seborrheic dermatitis is a topical skin inflammatory disorder, mainly characterized by yellow-grey scales and poorly defined erythematous patches
Fluconazole nanoparticles were prepared by the solvent evaporation method in six different batches
The optimization was based on particle size, percent entrapment efficiency, and in vitro drug release
Summary
Seborrheic dermatitis is a topical skin inflammatory disorder, mainly characterized by yellow-grey scales and poorly defined erythematous patches. It affects the sebum-rich areas such as skin, scalp, nasolabial folds, ears, eyebrows, and chest [1]. The frequency is more common in men than in women. The occurrence of the lesion depends on the weather conditions [2, 3]. Sunlight has some evidence to develop seborrheic dermatitis following psoralen+UVA therapy, known as PUVA. Treatment of seborrheic dermatitis aims at reducing inflammatory processes and decreasing sebum production [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
